EP2099420B8 - Nanocristaux pour une utilisation dans des formulations cosmétiques topiques et leur procédé de fabrication - Google Patents

Nanocristaux pour une utilisation dans des formulations cosmétiques topiques et leur procédé de fabrication Download PDF

Info

Publication number
EP2099420B8
EP2099420B8 EP07846641.4A EP07846641A EP2099420B8 EP 2099420 B8 EP2099420 B8 EP 2099420B8 EP 07846641 A EP07846641 A EP 07846641A EP 2099420 B8 EP2099420 B8 EP 2099420B8
Authority
EP
European Patent Office
Prior art keywords
nanocrystals
production
cosmetic formulations
topical cosmetic
topical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP07846641.4A
Other languages
German (de)
English (en)
Other versions
EP2099420B1 (fr
EP2099420A1 (fr
Inventor
Rolf Petersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmasol GmbH
Original Assignee
Pharmasol GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmasol GmbH filed Critical Pharmasol GmbH
Publication of EP2099420A1 publication Critical patent/EP2099420A1/fr
Publication of EP2099420B1 publication Critical patent/EP2099420B1/fr
Application granted granted Critical
Publication of EP2099420B8 publication Critical patent/EP2099420B8/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/044—Suspensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/602—Glycosides, e.g. rutin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/676—Ascorbic acid, i.e. vitamin C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/41—Particular ingredients further characterized by their size
    • A61K2800/413—Nanosized, i.e. having sizes below 100 nm
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/52—Stabilizers
    • A61K2800/524—Preservatives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP07846641.4A 2006-11-17 2007-11-19 Nanocristaux pour une utilisation dans des formulations cosmétiques topiques et leur procédé de fabrication Active EP2099420B8 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86623306P 2006-11-17 2006-11-17
PCT/EP2007/009943 WO2008058755A1 (fr) 2006-11-17 2007-11-19 Nanocristaux pour une utilisation dans des formulations cosmétiques topiques et leur procédé de fabrication

Publications (3)

Publication Number Publication Date
EP2099420A1 EP2099420A1 (fr) 2009-09-16
EP2099420B1 EP2099420B1 (fr) 2016-12-28
EP2099420B8 true EP2099420B8 (fr) 2017-03-15

Family

ID=39203932

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07846641.4A Active EP2099420B8 (fr) 2006-11-17 2007-11-19 Nanocristaux pour une utilisation dans des formulations cosmétiques topiques et leur procédé de fabrication

Country Status (4)

Country Link
US (1) US9114077B2 (fr)
EP (1) EP2099420B8 (fr)
CA (1) CA2669392C (fr)
WO (1) WO2008058755A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160045457A1 (en) 2005-09-09 2016-02-18 Ousama Rachid Epinephrine fine particles and methods for use thereof for treatment of conditions responsive to epinephrine
FR2947174B1 (fr) * 2009-06-24 2011-07-15 Oreal Composition cosmetique comprenant un polymere superabsorbant et un filtre uv organique
US8637569B2 (en) 2009-10-22 2014-01-28 Api Genesis, Llc Methods of increasing solubility of poorly soluble compounds and methods of making and using formulations of such compounds
KR101779910B1 (ko) 2009-10-22 2017-09-21 비쭈리 헬스 사이언스 엘엘씨 플라보노이드를 함유하는 조성물을 제조하는 방법 및 그의 사용 방법
AU2010335655B2 (en) * 2009-12-22 2015-03-05 Leo Pharma A/S Calcipotriol monohydrate nanocrystals
US20120322884A1 (en) * 2010-03-01 2012-12-20 University Of Manitoba Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
EP2544663B1 (fr) 2010-03-12 2018-01-03 Berg LLC Formulations intraveineuses de coenzyme q10 (coq10) et leurs procédés d'utilisation
US20140039031A1 (en) * 2011-02-23 2014-02-06 Dispersol Technologies. LLC Pharmaceutical formulations of acetyl-11-keto-b-boswellic acid, diindolylmethane, and curcumin for pharmaceutical applications
PE20180414A1 (es) 2011-06-17 2018-03-01 Berg Llc Composiciones farmaceuticas inhalables
EP2583672A1 (fr) 2011-10-17 2013-04-24 PharmaSol GmbH Nanocristaux et nanoparticules amorphes et leur procédé de production selon un processus à basse énergie
US20140242177A1 (en) 2011-10-21 2014-08-28 Nova Southeastern University Epinephrine nanoparticles, methods of fabrication thereof, and methods for use thereof for treatment of conditions responsive to epinephrine
CA2876883C (fr) 2012-06-15 2022-11-01 Nova Southeastern University Nanoparticules d'epinephrine, procede pour les fabriquer et procedes pour les utiliser pour le traitement d'affections repondant a l'epinephrine
US9072919B2 (en) 2012-10-12 2015-07-07 L'oreal S.A. Synergistic antioxidant cosmetic compositions containing at least one of baicalin and taxifolin, at least one of caffeine and nicotinamide, at least one of vitamin C and resveratrol and ferulic acid
US9018177B2 (en) 2012-10-12 2015-04-28 L'oreal S.A. Cosmetic compositions for increasing bioavailability of the active compounds baicalin and/or vitamin C
US9023826B2 (en) 2012-10-12 2015-05-05 L'oreal S.A. Compositions containing adenosine and the hydrotropes caffeine and nicotinamide for cosmetic use
EP2906547B2 (fr) 2012-10-12 2022-10-26 L'Oréal Compositions cosmétiques comprenant au moins un hydrotrope et au moins un composé actif
US9107853B2 (en) 2012-10-12 2015-08-18 L'oreal S.A. Compositions containing phenolic compounds and hydrotropes for cosmetic use
PT2976072T (pt) 2013-03-22 2021-08-12 Univ Nova Southeastern Partículas finas de epinefrina e métodos de utilização das mesmas para o tratamento de afeções que reagem à epinefrina
US9669242B2 (en) 2013-07-01 2017-06-06 L'oreal Compositions containing at least two phenolic compounds, a lipid-soluble antioxidant and at least one hydrotrope for cosmetic use
DE102014213314A1 (de) 2014-07-09 2016-01-14 Henkel Ag & Co. Kgaa Neuartiges Waschverfahren
CN104072512B (zh) * 2014-07-21 2016-08-24 江苏天晟药业有限公司 一种光甘草定的制备方法
BR102014028002B1 (pt) * 2014-10-31 2019-10-22 Univ Estadual Campinas Unicamp processo de obtenção de carreadores lipídicos nanoestruturados em copolímero tribloco, carreadores lipídicos nanoestruturados assim obtidos, e seus usos
CN105496802A (zh) * 2016-01-19 2016-04-20 上海应用技术学院 一种包覆维生素e醋酸酯的纳米固体脂质载体及其制备方法
CN105496801A (zh) * 2016-01-19 2016-04-20 上海应用技术学院 一种包覆维生素a棕榈酸酯的纳米固体脂质载体及其制备方法
CN105534724A (zh) * 2016-01-19 2016-05-04 上海应用技术学院 一种包覆白藜芦醇的纳米固体脂质载体及其制备方法
ITUA20164065A1 (it) * 2016-06-01 2017-12-01 Probiotical Spa Composizioni in gel per applicazioni topiche a base di batteri, preparazione delle stesse e loro usi.
CN108014074B (zh) * 2016-10-31 2020-12-08 常州药物研究所有限公司 纳米白藜芦醇混悬液的制备方法和包含纳米白藜芦醇混悬液的化妆品组合物
CN106667910B (zh) * 2017-01-12 2021-02-02 西南大学 一种谷维素鱼油纳米乳液及其制备方法和应用
KR102540472B1 (ko) 2017-08-11 2023-06-08 (주)아모레퍼시픽 (r)-n-[1-(3,5-다이플루오로-4-메테인설폰일아미노-페닐)-에틸]-3-(2-프로필-6-트라이플루오로메틸-피리딘-3-일)-아크릴아마이드를 함유하는 약학 조성물
KR20190024734A (ko) 2017-08-31 2019-03-08 (주)아모레퍼시픽 병풀 추출물 또는 이로부터 유래한 트리테르펜을 고함량으로 포함하는 화장료 조성물 및 이의 제조 방법
WO2019094625A1 (fr) * 2017-11-09 2019-05-16 Nexien Biopharma, Inc. Procédés et compositions d'administration parentérale de cannabidiol dans le traitement de troubles convulsifs
CN109157512B (zh) * 2018-11-09 2021-03-05 辽宁大学 一种莪术醇衍生物纳米晶的制备方法
CN109846776A (zh) * 2019-01-30 2019-06-07 广州诗美化妆品有限公司 一种积雪草提取液及其制备方法和应用
CN110448534A (zh) * 2019-07-29 2019-11-15 兰州大学 一种大黄游离蒽醌自微乳化片及其制备方法
CN110551137B (zh) * 2019-09-29 2022-06-10 浙江惠松制药有限公司 一种光甘草定的提取纯化方法以及在化妆品中的用途
CN110538137B (zh) * 2019-09-30 2023-01-17 辽宁大学 秦皮甲素纳米混悬凝胶剂及其制备方法与应用
JP2023550363A (ja) 2020-11-17 2023-12-01 アーキュティス・バイオセラピューティクス・インコーポレーテッド 深部皮膚薬物送達のための組成物および方法
AU2021405419A1 (en) * 2020-12-23 2023-08-03 11584022 Canada Inc. Homogeneous biopolymer suspensions, processes for making same and uses thereof
FR3133125A1 (fr) * 2022-03-06 2023-09-08 Laurent Blasco compositions cosmetiques sous la forme d’émulsions à saturation de phases et leur utilisation en application topique.

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3623376A1 (de) * 1986-07-11 1988-01-21 Behringwerke Ag Pharmazeutische formulierung und verfahren zu deren herstellung
NL194638C (nl) 1986-12-19 2002-10-04 Novartis Ag Hydrosol die vaste deeltjes van een farmaceutisch actieve stof bevat en farmaceutisch preparaat dat deze hydrosol bevat.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
MX9201782A (es) 1991-04-19 1992-10-01 Sandoz Ag Particulas de sustancias biologicamente activas, sustancialmente insolubles en agua, proceso para su produccion y composicion farmaceutica que las contiene.
DE4131562A1 (de) 1991-09-18 1993-03-25 Medac Klinische Spezialpraep Arzneistofftraeger aus festen lipidteilchen-feste lipidnanosphaeren (sln)
GB9121153D0 (en) 1991-10-04 1991-11-13 Tioxide Chemicals Ltd Method of preparing sunscreens
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
US5827539A (en) * 1995-12-28 1998-10-27 Amway Corporation Dry carotenoid-oil powder and process for making same
DE19609476A1 (de) * 1996-03-11 1997-09-18 Basf Ag Stabile zur parenteralen Verabreichung geeignete Carotinoid-Emulsionen
WO2000067800A2 (fr) 1999-05-07 2000-11-16 Pharmasol Gmbh Excipient pour l'administration controlee de principe actif, produit a partir de conjugues matrice lipidique-substance pharmaceutique
WO2000067728A2 (fr) 1999-05-07 2000-11-16 Pharmasol Gmbh Particules lipidiques a base de melanges de lipides liquides et solides et procede pour les produire
DE19932157A1 (de) 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
KR100903896B1 (ko) * 1999-07-13 2009-06-19 체엘에르-헤미쉐스 라보라토리움 독토르 쿠르트 리히터 게엠베하 건강상 해로운 자외선으로부터 보호하고 천연 피부보호막을 강화시키기 위한 자외선 보호용 조성물
AU2002239504A1 (en) * 2000-12-06 2002-06-18 Pharmacia Corporation Laboratory scale milling process
US6979440B2 (en) 2001-01-29 2005-12-27 Salvona, Llc Compositions and method for targeted controlled delivery of active ingredients and sensory markers onto hair, skin, and fabric
FR2820320B1 (fr) * 2001-02-02 2003-04-04 Oreal Suspension de nanospheres de principe actif lipophile stabilisee par des polymeres hydrodispersibles
US7112340B2 (en) 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
GB0127832D0 (en) 2001-11-20 2002-01-09 Jagotec Ag Method for the preparation of pharmaceutical nanosuspensions
US7067152B2 (en) 2002-04-17 2006-06-27 Salvona Llc Multi component moisture triggered controlled release system that imparts long lasting cooling sensation on the target site and/or provides high impact fragrance or flavor burst
US6767396B2 (en) * 2002-07-01 2004-07-27 Nu-Kote International, Inc. Process for the preparation of aqueous magnetic ink character recognition ink-jet ink compositions
EP1569623B1 (fr) 2002-12-13 2008-10-15 Jagotec Ag Preparation topique de spironolactone nanoparticulaire
EP1904053B1 (fr) 2005-06-29 2011-08-17 DSM IP Assets B.V. Nanoparticules d'isoflavone et utilisation correspondante
KR101314689B1 (ko) * 2005-06-29 2013-10-07 디에스엠 아이피 어셋츠 비.브이. 아이소플라본의 나노입자를 포함하는 국소용 조성물

Also Published As

Publication number Publication date
WO2008058755A1 (fr) 2008-05-22
CA2669392A1 (fr) 2008-05-22
CA2669392C (fr) 2016-05-10
EP2099420B1 (fr) 2016-12-28
EP2099420A1 (fr) 2009-09-16
US20100047297A1 (en) 2010-02-25
US9114077B2 (en) 2015-08-25

Similar Documents

Publication Publication Date Title
EP2099420B8 (fr) Nanocristaux pour une utilisation dans des formulations cosmétiques topiques et leur procédé de fabrication
EP2044927A4 (fr) Produit cosmétique et procédé pour la production de celui-ci
IL177716A0 (en) Pharmaceutical composition for topical use in form of xerogels or films and methods for production
EP2170248A4 (fr) Applicateur cosmétique et procédé de fabrication
EP1998788A4 (fr) Compositions et procédés pour le traitement topique de troubles dermatologiques répondants au goudron
GB2431876B (en) Use of para-coumaric acid or para-hydroxycinnamic acid derivatives in cosmetic or dermatological compositions
WO2008106102A9 (fr) Inhibiteurs de rtp801 et leur utilisation dans le traitement de diverses maladies
EP2219600A4 (fr) Compositions cosmétiques topiques d'éclaircissement de la peau et leurs procédés d'utilisation
EP2047842A4 (fr) Produit cosmétique et son procédé de production
EP1942912A4 (fr) Agent pour application sur une muqueuse et méthode de production dudit agent
WO2007022245A3 (fr) Systeme d'observance par un patient et methode de promotion de l'observance
EP2282746B8 (fr) Compositions et méthodes utilisant des cellules souches dans la cicatrisation de plaies cutanées
PT1743015E (pt) Composição tensioactiva, processo de preparação e produto cosmético que compreende a dita composição
EP2086561A4 (fr) Formulation topique et ses utilisations
EP2405886B8 (fr) Compositions de soins personnels et pharmaceutiques topiques et leurs utilisations
EP1820538A4 (fr) Produit cosmetique et procede de production correspondant
EP2076558B8 (fr) Composition comprenant du néopentasilane et procédé de préparation
HK1131553A1 (zh) 用於治療皮膚的美容組合物以及用於治療皮膚的方法
WO2009155116A9 (fr) Procédés de réduction de la douleur et de l'inflammation
PT1839644T (pt) Nanoemulsão, método da sua produção e composição cosmética e dermatológica que a contém
PL2120845T3 (pl) Nanocząstki do stosowania w preparatach kosmetycznych i dermatologicznych
PL2066408T3 (pl) Kompozycja na bazie ksantoksyliny i jej zastosowanie w kosmetyce
EP1925231A4 (fr) Outil de soin pour la peau et son procede de fabrication
IL185480A0 (en) Topical formulations of borinic acid antibodies and their methods of use
EP2004161B8 (fr) Composition orale comprenant de l'adh et de la génistéine pour améliorer l'apparance cutané

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090617

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20111212

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ABBVIE DEUTSCHLAND GMBH & CO KG

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602007049358

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: A61K0008340000

Ipc: A61K0008040000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: B82Y 5/00 20110101ALI20160610BHEP

Ipc: A61K 8/06 20060101ALI20160610BHEP

Ipc: A61K 8/67 20060101ALI20160610BHEP

Ipc: A61K 8/49 20060101ALI20160610BHEP

Ipc: A61K 8/04 20060101AFI20160610BHEP

Ipc: A61K 8/60 20060101ALI20160610BHEP

Ipc: A61Q 19/00 20060101ALI20160610BHEP

Ipc: A61K 8/34 20060101ALI20160610BHEP

INTG Intention to grant announced

Effective date: 20160707

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 856691

Country of ref document: AT

Kind code of ref document: T

Effective date: 20170115

RAP2 Party data changed (patent owner data changed or rights of a patent transferred)

Owner name: PHARMASOL GMBH

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602007049358

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170329

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20161228

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 856691

Country of ref document: AT

Kind code of ref document: T

Effective date: 20161228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170428

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170328

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20170428

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602007049358

Country of ref document: DE

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

26N No opposition filed

Effective date: 20170929

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: R.A. EGLI AND CO, PATENTANWAELTE, CH

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171119

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20071119

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20161228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20161228

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231129

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231129

Year of fee payment: 17

Ref country code: DE

Payment date: 20231127

Year of fee payment: 17

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240110

Year of fee payment: 17